Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Recruiting phase 2 trial modulating therapy for locally advanced nasopharyngeal carcinoma based on plasma EBV DNA level after induction chemotherapy (planned n=198).

Fudan University